Abstract
Background Myotonic dystrophy type 1 (DM1) is a prevalent inherited muscular dystrophy in adults, affecting distal muscles such as the gastrocnemius, soleus, and tibialis anterior. This leads to significant gait deviations and reduced walking speed, impacting overall well-being and increasing fall risk.
Objective This study aimed to assess how walking speed affects gait kinematics in individuals with DM1.
Method Eighteen individuals with genetically confirmed DM1 (4 women, age: 41.0 [35.5; 47.8] years, mass: 76.8 [67.1; 94.6] kg, height: 166.0 [156.7; 173.3] cm) participated in this study. Each participant walked barefoot along a 13-meter walkway at comfortable and fast speeds. Subsequently, spatiotemporal parameters and joint kinematics were assessed.
Results The step length (p < 0.001), cycle speed (p < 0.001), and cadence (p < 0.001) increased significantly, leading to a higher walking speed. Moreover, the vertical amplitude of the center of mass (CoM) increased significantly (p = 0.015), while the mediolateral amplitude decreased (p = 0.001) at fast walking condition. In addition, significant kinematic changes included increased trunk tilt (p < 0.001), greater anterior pelvic tilt (p < 0.001), increased hip flexion at initial contact, and enhanced knee flexion during both stance and swing phases. Ankle dorsiflexion showed a trend towards increase during stance phase (p = 0.055) at fast walking condition.
Conclusions Fast walking speed in individuals with DM1 lead to significant gait adaptations. These adaptations reflect compensatory mechanisms to manage muscle weakness. The present study revealed significant changes in spatiotemporal parameters related to walking speed. Fast walking also highlighted kinematic adaptations in trunk, pelvis and lower limb joints. These findings enhance our understanding of gait deviation in individuals with DM1 and suggest the potential benefits of targeted fast walking training in this population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project received approval from the ethics committee of the Centre de Recherche Interdisciplinaire en Adaptation Readaptation (Montreal, Canada). All participants provided their informed consent before participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
none
